未知生产厂商
The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada. The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. VLPs are thought to have multiple mechanisms involving the immune system which engage both humoral and cellular responses. In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known as ISS-1018), meant to provide an enhanced immune response to the vaccine. In addition, Medicago partnered with GlaxoSmithKline (GSK) to test its adjuvant, AS03. A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity of this vaccine candidate with or without either Cpg 1018 or AS03 (NCT04450004) in adults aged 18-55 years.
The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada. The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. VLPs are thought to have multiple mechanisms involving the immune system which engage both humoral and cellular responses. In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known as ISS-1018), meant to provide an enhanced immune response to the vaccine. In addition, Medicago partnered with GlaxoSmithKline (GSK) to test its adjuvant, AS03. A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity of this vaccine candidate with or without either Cpg 1018 or AS03 (NCT04450004) in adults aged 18-55 years.
